Kei Kishimoto

Kei Kishimoto

Company: Selecta Biosciences

Job title: CSO


Dr. Kishimoto is the Chief Scientific Officer of Selecta Biosciences, a biotechnology company developing synthetic vaccines based on a novel self-assembling nanoparticle technology.  Prior to joining Selecta, Dr. Kishimoto was Vice President of Research at Momenta Pharmaceuticals where he led multidisciplinary teams in inflammation, oncology, and cardiovascular disease.  Previously he was Senior Director of Inflammation Research at Millennium Pharmaceuticals, where he provided the scientific leadership for four programs in clinical development, and an Associate Director of Immunology at Boehringer Ingelheim.  Dr. Kishimoto received his doctoral degree in Immunology from Harvard University and his post-doctoral training at Stanford University.


Mitigation of Immunogenicity to Enable Re-Dosing of AAV Vectors by Co-Administration with Tolerogenic ImmTOR Nanoparticles 9:45 am

Co-administration of ImmTOR nanoparticles with AAV inhibits the formation of anti-AAV antibodies and enables vector re-dosing In addition, admixing of ImmTOR to AAV has a beneficial first dose effect on enhancing transgene expression in the liver Clinical proof-of-concept has been established with ImmTOR combined with a highly immunogenic enzyme therapyRead more

day: Discussion Day

Panel Discussion: Comparing and Contrasting Immunosuppression and Novel Approaches 3:00 pm

Discussing the most promising approaches to overcome immunogenicity Investigating which approaches are most applicable to different indications Recognizing the importance of novel technologies in the immunology spaceRead more

day: Discussion Day

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.